CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $69.69.

Several brokerages recently weighed in on CRSP. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. Citigroup raised their price objective on CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Wells Fargo & Company decreased their price target on CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target on CRISPR Therapeutics, a potentially supportive signal for investor sentiment; the report did not provide the new target in the available details. Citigroup price target report
• Positive Sentiment: Brookline Capital Markets substantially improved its forecasts, revising projected losses to $4.74 per share for FY2026 from $5.63 and to $3.83 for FY2027 from $4.51. HC Wainwright also made smaller upward adjustments to several quarterly and annual estimates and maintains a Buy rating. Better-than-previous forecasts could support the shares, although losses remain expected. Brookline Capital Markets comments CRISPR Therapeutics analyst estimates
• Neutral Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, indicating a more cautious view than the Buy calls but not a direct downgrade. RBC Capital Hold rating
• Neutral Sentiment: CRSP is attracting increased attention among Zacks.com users, but the “trending stock” coverage does not itself report a new business or clinical development. Zacks trending-stock article

Insiders Place Their Bets

In related news, Director Ali Behbahani sold 13,679 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the completion of the sale, the director owned 16,637 shares of the company’s stock, valued at $949,806.33. This trade represents a 45.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the completion of the sale, the chief executive officer owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 93,558 shares of company stock worth $4,881,663 in the last quarter. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently modified their holdings of the stock. Compass Financial Management LLC acquired a new stake in CRISPR Therapeutics in the third quarter worth $25,000. Versant Capital Management Inc boosted its position in shares of CRISPR Therapeutics by 175.1% during the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth about $56,000. GAMMA Investing LLC boosted its position in shares of CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after purchasing an additional 597 shares in the last quarter. Finally, Hollencrest Capital Management boosted its holdings in CRISPR Therapeutics by 249.9% in the first quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after acquiring an additional 937 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $50.07 on Tuesday. The stock has a market cap of $4.86 billion, a P/E ratio of -10.56 and a beta of 1.92. The company has a current ratio of 16.21, a quick ratio of 17.85 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average is $53.28 and its 200-day moving average is $52.81. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $63.45.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The business had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics’s revenue for the quarter was up 1311.1% on a year-over-year basis. Equities research analysts anticipate that CRISPR Therapeutics will post -4.50 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.